APT 3111

Drug Profile

APT 3111

Alternative Names: APT 2392; CD59-Prodaptin

Latest Information Update: 02 Aug 2005

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Inflazyme Pharmaceuticals
  • Class
  • Mechanism of Action CD59 antigen agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Paroxysmal nocturnal haemoglobinuria

Highest Development Phases

  • Discontinued Paroxysmal nocturnal haemoglobinuria

Most Recent Events

  • 30 Apr 2005 Discontinued - Preclinical for Paroxysmal nocturnal haemoglobinuria in United Kingdom (unspecified route)
  • 21 Apr 2004 Adprotech has been acquired by Inflazyme Pharmaceuticals
  • 19 May 2003 APT 3111 has received orphan drug status for paroxysmal nocturnal haemoglobinuria in United Kingdom
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top